Abstract
The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Current Gene Therapy
Title: Small Interfering RNA: A New Tool for Gene Therapy
Volume: 3 Issue: 5
Author(s): Feng Bi, Na Liu and Daiming Fan
Affiliation:
Keywords: Gene Therapy, anti-gene medicines, oligonucleotides, ribozymes
Abstract: The use of anti-gene agents to disrupt the expression of disease-related genes could potentially be of utility in the treatment of a large number of illnesses, including most neoplasms. Traditional anti-gene agents include antisense oligonucleotides and ribozymes. Recent observations have provided evidence for another promising anti-gene technology-RNA interference (RNAi), in which the introduced double-stranded RNA (dsRNA), after a complicated series of processing steps, disrupts the expression of the targeted cellular gene. Further studies have indicated that small interfering RNAs (siRNAs) of generally 21 ∼ 23 nucleotides, which resemble the processing products of long dsRNA, can induce RNAi directly in mammalian cells. Because of their high specificity and efficiency, siRNAs might be a new class of anti-gene medicines for gene therapy applications.
Export Options
About this article
Cite this article as:
Bi Feng, Liu Na and Fan Daiming, Small Interfering RNA: A New Tool for Gene Therapy, Current Gene Therapy 2003; 3 (5) . https://dx.doi.org/10.2174/1566523034578203
DOI https://dx.doi.org/10.2174/1566523034578203 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atopic Dermatitis and Cytokines: The Immunoregulatory and Therapeutic Implications of Cytokines in Atopic Dermatitis - Part II: Negative Regulation and Cytokine Therapy in Atopic Dermatitis
Recent Patents on Inflammation & Allergy Drug Discovery Mechanisms Involved in the Increased Hemolysis in the Fetus and Newborn
Current Pediatric Reviews Attenuated D2 16681-PDK53 Vaccine: Defining Humoral and Cell- Mediated Immunity
Current Pharmaceutical Design Berberine in the Treatment of Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Adenosine Receptors: New Therapeutic Targets for Inflammation in Diabetic Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Cannabinoids and Psychosis
Current Pharmaceutical Design Structural and Molecular Basis of Carbohydrate-Protein Interaction Systems as Potential Therapeutic Targets
Current Pharmaceutical Design Macrocycle Molecules for the Management of Systemic Infections: the Clarithromycin Paradigm
Current Topics in Medicinal Chemistry Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy The Anti-Inflammatory Effects of Anacardic Acid on a TNF-α - Induced Human Saphenous Vein Endothelial Cell Culture Model
Current Pharmaceutical Biotechnology SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis
Current Vascular Pharmacology High Glucose-Mediated Imbalance of Nitric Oxide Synthase and Dimethylarginine Dimethylaminohydrolase Expression in Endothelial Cells
Current Neurovascular Research Wolbachia and Its Implications for the Immunopathology of Filariasis
Endocrine, Metabolic & Immune Disorders - Drug Targets Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine
Anti-Cancer Agents in Medicinal Chemistry Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Pt2L4 Protein, a Homologue to Hev b 5 from Rubber Tree, May Not Be Responsible for the Cross-Reactions to Cassava Show by People Allergic to Latex
Protein & Peptide Letters Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Antiphospholipid Syndrome: Characteristics and Obstetrical Management
Current Drug Targets Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases
Current Vascular Pharmacology